Rice lab’s injectable gel feeds steady dose of drugs to tumor cells
An immunotherapy drug embedded in a slow-release hydrogel invented at Rice University in collaboration with the University of Texas Health Science Center at Houston (UTHealth) appears to be highly effective at killing cancer cells.
STINGel combines a new class of immunotherapy drugs called stimulator of interferon gene (STING) agonists with an injectable hydrogel that releases the drug in a steady dose to activate the immune system to kill cancer cells. It was developed by the Rice lab of chemist and bioengineer Jeffrey Hartgerink and Rice alum Simon Young, an assistant professor of oral and maxillofacial surgery at UTHealth.
In clinical trials, immunotherapy drugs have demonstrated strong cancer-fighting abilities. Research has also found that the drugs are flushed quickly from the body, and current trials require multiple injections.
The new research, which is detailed in Biomaterials, showed that slow-release peptide gels could continuously deliver immunotherapy drugs to tumor sites for long periods of time.
Hartgerink is a pioneer in the development of self-assembling multidomain peptide (MDP) hydrogels, which mimic the body’s extracellular matrix to encourage the growth of cells and vascular systems for tissue repair. The hydrogel is injected as a liquid, turns semisolid inside the body and slowly degrades over time.
The hydrogel in the new study is also welcoming to cells, but when the invaders are cancer cells, they’re in for trouble. Immunotherapy drugs known as cyclic dinucleotides (CDNs) await them inside the gel.
Hartgerink, a professor of chemistry and bioengineering, said the concentration of CDN in the hydrogel is important.
“The normal approach to CDN delivery is simple injection, but this leads to very rapid diffusion of the drug throughout the body and reduces its concentration at the site of the tumor to very low levels,” he said. “Using the same amount of CDN, the STINGel approach allows the concentration of CDN near the tumor to remain much higher for long periods of time.”
STINGel was studied both in lab cultures and in vivo. For the in vivo portion, six groups of 10 rodents each were treated with CDN alone, control collagens alone or with CDN, MDP alone or STINGel (CDN plus MDP). Only one in 10 CDN or collagen plus CDN animals survived 105 days, but six of 10 animals treated with STINGel survived. These also proved resistant to further implantation of cancer cells, meaning their immune systems were trained to successfully identify and destroy both the existing cancer and future occurrence of that cancer, Hartgerink said.
The lab tested more common hydrogels but found that they were unable to provide the same controlled release and also failed to provide an additional benefit over CDN treatment seen in clinical trials. “The MDP hydrogel provides a unique environment for the release of CDN that other gels just can’t match,” Hartgerink said.
“The CDN we used in this study is currently in clinical trials,” he said. “We think that our STINGel approach has the potential to significantly broaden the scope of this powerful immunotherapy drug to a larger range of resistant cancers.”
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- Study reveals cancer immunotherapy patients at most risk of life-threatening side effectson April 13, 2021 at 9:33 am
Immune checkpoint inhibitors boost a patient's immune response against cancer cells, but they can cause potentially life-threatening side effects in some individuals. New research may help clinicians ...
- Therapeutic cancer vaccine shows promise against multiple tumor typeson April 13, 2021 at 7:47 am
Marc Baum went through all the usual steps to treat his bladder cancer—a couple of surgeries, radiation therapy and chemotherapy, all in a three-month period.
- Adverse Reactions to Immunotherapy Can Appear After a Yearon April 13, 2021 at 6:58 am
"We are definitely seeing delayed reactions to immunotherapy in our practice" in several organ systems, including the skin, said Jennifer Choi, MD, chief of oncodermatology at Northwestern ...
- Personalized cancer vaccine deemed safe, shows potential benefit against canceron April 13, 2021 at 5:58 am
"While immunotherapy has revolutionized the treatment of cancer, the vast majority of patients do not experience a significant clinical response with such treatments," said study author Thomas Marron, ...
- AmunBio and NorthShore University HealthSystem to Advance Cancer Immunotherapy with Next Generation Engineered Oncolytic Viruseson April 13, 2021 at 4:00 am
This technology forms the core of AmunBio's proprietary, multimodal therapeutic approach utilizing direct destruction of cancer cells and immune system activation. The technology is based on more ...
- Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021 American Association for Cancer Research Annual Meetingon April 12, 2021 at 11:55 pm
B7H7 is a novel immune checkpoint of B7 family, which is highly expressed on a variety of human cancers including colon, pancreatic, kidney, breast, bladder, lung cancers, etc. and is associated ...
- Exercise training may slow breast cancer growth by increasing anti-tumor immune responseon April 12, 2021 at 5:09 pm
Exercise training may slow tumor growth and improve outcomes for females with breast cancer - especially those treated with immunotherapy drugs - by stimulating naturally occurring immune mechanisms, ...
- Yale researchers provide new insights into acquired resistance to cancer immunotherapyon April 12, 2021 at 4:51 pm
a form of cancer immunotherapy. The study was presented today at the American Association of Cancer Research (AACR) virtual annual meeting. Acquired resistance to immune checkpoint inhibitors is a ...
- Cancer Immunotherapy Market Size Worth USD 153.03 Billion by 2027, Market Trends – Growing Health Awareness and Effectiveness of Treatmenton April 12, 2021 at 2:35 pm
The global Cancer Immunotherapy Market is expected to reach USD 153.03 Billion by 2027, according to a new report by Emergen Research. The cancer immunotherapy market is growing at a substantial pace ...
- Cancer-killing virus shows promise for inoperable skin tumourson April 12, 2021 at 2:45 am
Scientists from NYU Langone Health tested whether the common-cold pathogen coxsackievirus boosts the action of an immunotherapy drug, which helps the immune system detect and kill cancer cells. An ...
via Bing News